Related Experiment Videos

High or low dose of angiotensin-converting enzyme inhibitor in patients with left ventricular dysfunction?

H Pouleur1

  • 1Department of Physiology and Pharmacology, University of Louvain, School of Medicine, Brussels, Belgium.

Insights

High-dose angiotensin-converting enzyme inhibitors are crucial for treating congestive heart failure. Evidence shows increased efficacy and tolerability with higher doses, recommending their use in heart failure patients.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Angiotensin-converting enzyme inhibitors (ACEIs) are standard in congestive heart failure (CHF) treatment.
  • Optimal dosing of ACEIs in CHF remains debated, with significant inter-physician and international variations.

Purpose of the Study:

  • To evaluate the optimal dosage of ACEIs for patients with congestive heart failure.
  • To address the controversy surrounding ACEI dosing in CHF management.

Main Methods:

  • Review of objective data and findings from large mortality trials involving ACEIs in heart failure.
  • Analysis of drug efficacy relative to dosage.

Main Results:

  • ACEI efficacy in heart failure demonstrably increases with higher doses.
  • Most patients with heart failure tolerate high doses of ACEIs well, as evidenced in major trials.

Conclusions:

  • High-dose ACEIs should be prioritized for heart failure patients.
  • Maximize ACEI dosage in CHF unless new evidence suggests otherwise.

Related Concept Videos